Blackstone (BX) Commits $400 Million With Teva to Advance Duvakitug Clinical Development

Core Insights - Blackstone Inc. is recognized as one of the top 10 best asset management stocks to buy currently [1] Group 1: Investment and Strategic Partnerships - Blackstone Life Sciences has entered a strategic funding agreement worth $400 million with Teva Pharmaceuticals to accelerate the clinical development of duvakitug, a monoclonal antibody targeting TL1A [2] - The investment will be distributed over four years, with Blackstone set to receive regulatory milestones and low single-digit global royalties upon FDA approval [2] Group 2: Clinical Development and Market Potential - Duvakitug is positioned as a potential best-in-class therapy in a significant and expanding market, with ongoing Phase 3 trials for ulcerative colitis and Crohn's disease following successful Phase 2b data [3] - The collaboration between Teva and Sanofi is highlighted as well-positioned to develop and commercialize this important medicine [3] Group 3: Analyst Coverage and Market Outlook - Barclays analyst Benjamin Budish has reinstated coverage of Blackstone with an Equal Weight rating and a price target of $126, maintaining unchanged ratings and earnings estimates [3]